NASDAQ:GILD 2 April 2026

Gilead Stock Gets FDA Nod, But Investors Face Hurdle
····

Gilead Stock Gets FDA Nod, But Investors Face Hurdle

Gilead Sciences will get its first U.S. session move on Hepcludex Tuesday, after winning FDA approval as the first chronic hepatitis delta virus treatment. The stock was last at $134.36, with markets shut Monday for Memorial Day. Timing is key here. Gilead is working to show growth outside its main HIV business as it leans on new liver-disease and cancer drugs to make up for shrinking sales in older drugs and costs from recent acquisitions.
May 26, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK plc wrapped up changes to ViiV Healthcare’s ownership structure on April 1. After Pfizer’s exit from the HIV-focused joint venture, Japan’s Shionogi bumped its stake up to 21.7%. GSK remains the majority owner with 78.3%, the company said. Timing is crucial here: ViiV is a core growth driver as GSK shifts focus toward specialty medicines. For 2025, GSK reported an 11% increase in HIV sales to 7.7 billion pounds, fueling a 17% jump in specialty medicines revenue.
April 2, 2026